Adrian Dawkes talks to PharmaVentures Founder and CEO Fintan Walton about his experience from over 30 years of dealmaking. In particular, why innovator biotechs and their investors are weaker when they underestimate the significance of both understanding and communicating their commercial strategy for their lead assets in negotiations. Hear about: • Failing to understand the inherent risks at the commercial stage is a failure of investment logic.• Why you shouldn't expect a potential partner to have any answers to the commercial path and success of your asset• Why you should know where your assets fit in the market landscape and what differentiates it commercially.• How to apply commercial strategic thinking to very early-stage assets. • How planning to avoid commercial risk reduces investment risk.